Skip to content

Single center, randomized controlled study on antibacterial, regulating bacterial balance and repairing barrier function in the treatment of balanoposthitis

Single center, randomized controlled study on antibacterial, regulating bacterial balance and repairing barrier function in the treatment of balanoposthitis

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016901
Enrollment
Unknown
Registered
2018-07-01
Start date
2018-07-02
Completion date
Unknown
Last updated
2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Balanoposthitis

Interventions

Group A:Fusidic Acid Cream+Hyaluronic acid repair biofilm
Group B:Hyaluronic acid repair biofilm+:Living Preparation of Lactobacillus capsule
Group C:Fusidic Acid Cream+Hyaluronic acid repair biofilm+:Living Preparation of Lactobacillus capsule

Sponsors

1st Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Chinese men over the age of 18 years; 2. Clinically diagnosed as "balanoposthitis" caused by infectious factors; 3. No skin disease at the measurement site or systemic disease affecting the skin; 4. Informed consent for the purpose and content of the study, and can be followed up as required.

Exclusion criteria

Exclusion criteria: 1. In the last 3 months, drug that has been used by dermatologists to contradict this study, especially in 2 weeks, has been used in the test area for anti - inflammatory drugs or for the use of corticosteroids within 1 months; 2. Chronic diseases such as hypertension, diabetes, liver and kidney dysfunction; 3. Undergo organ resection (kidney, lung, spleen, liver...) In the past 5 years, there has been a history of extensive mental loss caused by craniocerebral trauma or a legacy of sequelae; 4. A person suffering from a chronic disease or a long-term treatment; an author of an allergic state or asthma, a drug intolerance of a background or a person receiving antiallergic treatment; a person suffering from a disease of the immune system or a person receiving immunosuppressive therapy; 5. There are some skin diseases or harbingers or some skin defects that may affect the measurement of the skin; 6. A person sensitive or allergic to the drugs used.

Design outcomes

Primary

MeasureTime frame
Skin barrier function;skin flora;

Countries

China

Contacts

Public ContactLi Zhang

1st Hospital of China Medical University

lizhang_1001@126.com+86 13940023570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026